Scholar Rock/$SRRK
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Scholar Rock
Scholar Rock Holding Corp is a late-stage biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for treating serious diseases in which signaling by protein growth factors plays a fundamental role. Its pipeline includes Neuromuscular and Obesity, Immuno-oncology, Fibrotic Disease, and Hematology. The group operates and manages its business as a single segment to assess performance and make operating decisions.
Ticker
$SRRK
Sector
Primary listing
Employees
128
Headquarters
Website
Scholar Rock Metrics
BasicAdvanced
$2.8B
-
-$3.29
0.49
-
Price and volume
Market cap
$2.8B
Beta
0.49
52-week high
$46.98
52-week low
$22.71
Average daily volume
3.4M
Financial strength
Current ratio
6.327
Quick ratio
5.888
Long term debt to equity
24.14
Total debt to equity
26.374
Interest coverage (TTM)
-50.40%
Profitability
EBITDA (TTM)
-321.685
Management effectiveness
Return on assets (TTM)
-71.29%
Return on equity (TTM)
-172.08%
Valuation
Price to book
12.09
Price to tangible book (TTM)
12.09
Price to free cash flow (TTM)
-10.923
Free cash flow yield (TTM)
-9.15%
Free cash flow per share (TTM)
-2.689
Growth
Earnings per share change (TTM)
29.04%
3-year earnings per share growth (CAGR)
0.11%
What the Analysts think about Scholar Rock
Analyst ratings (Buy, Hold, Sell) for Scholar Rock stock.
Bulls say / Bears say
Apitegromab is projected to generate approximately $2 billion in annual revenue by the early 2030s, signaling substantial commercial potential for Scholar Rock’s lead therapy alongside growing demand for muscle-preserving treatments (Reuters)
The FDA accepted Scholar Rock’s Biologics License Application for apitegromab under priority review, and the EMA validated its marketing application, positioning the company for a U.S. launch in late 2025 and a European launch in 2026 (Business Wire)
Positive Phase 2 EMBRAZE trial results demonstrated that apitegromab preserved 54.9% of lean mass during 24 weeks of tirzepatide-induced weight loss, confirming the drug’s differentiated value in cardiometabolic indications (Business Wire)
On September 23, 2025, the FDA issued a complete response letter declining to approve apitegromab due to observations at Catalent’s Indiana fill-finish facility, triggering a 12% premarket drop and highlighting regulatory and manufacturing execution risks (Reuters)
Scholar Rock has 17,362,147 pre-funded warrants and 8,678,664 warrants outstanding, posing significant potential dilution to existing shareholders upon exercise (SEC)
Data summarised monthly by Lightyear AI. Last updated on 4 Oct 2025.
Scholar Rock Financial Performance
Revenues and expenses
Scholar Rock Earnings Performance
Company profitability
Scholar Rock News
AllArticlesVideos
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire2 weeks ago
Scholar Rock's Spinal Muscular Atrophy Drug Faces FDA Delay Over Catalent Indiana Inspection
Benzinga1 month ago
Scholar Rock, A Top 10% Stock, Dives After Catalent Issues Hamper SMA Drug
Investors Business Daily1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Scholar Rock stock?
Scholar Rock (SRRK) has a market cap of $2.8B as of October 31, 2025.
What is the P/E ratio for Scholar Rock stock?
The price to earnings (P/E) ratio for Scholar Rock (SRRK) stock is 0 as of October 31, 2025.
Does Scholar Rock stock pay dividends?
No, Scholar Rock (SRRK) stock does not pay dividends to its shareholders as of October 31, 2025.
When is the next Scholar Rock dividend payment date?
Scholar Rock (SRRK) stock does not pay dividends to its shareholders.
What is the beta indicator for Scholar Rock?
Scholar Rock (SRRK) has a beta rating of 0.49. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.